So far you’ve made a baseless claim about the FDA being a better source for survival rates, just to throw more snark. You’ve totally misunderstood the requirement for a placebo in a double blinded RCT. And now all you have is ad hominem.
There was no KoolAid in my post, I just used the numbers supplied by the company to point out the issues with an RCT for the indicated subgroup. ValueMiner001 supplied a link to a paper that backs exactly what I said regarding the difficulty they will have getting the academic institutes to participate, but you just call it all garbage and snarkly dismiss it but can’t back up any of your claims.
Ann: Update on BLA for Graft Versus Host Disease, page-749
-
- There are more pages in this discussion • 269 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.010(0.69%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.49 | $1.44 | $3.472M | 2.379M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12398 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 5440 | 3 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |